Lantid 30 mg is indicated for:

• Short-term treatment of active duodenal ulcer
• Maintenance of healed duodenal ulcers
• Short-term treatment of active benign gastric ulcers
• Short-term treatment of active erosive esophagitis
• Maintenance of healing of erosive esophagitis
• Pathological hypersecretory conditions including Zollinger-Ellison Syndrome
• H. pylori eradication to reduce the risk of duodenal ulcer recurrence

Lansoprazole is a substituted benzimidazole and is also known as a PPI due to its property of blocking the final step of acid secretion by inhibiting the H⁺/K⁺ ATPase enzyme system in the gastric parietal cell. Both basal and stimulated acid secretion are inhibited.

Benign gastric ulcer: 30 mg daily in the morning for 8 weeks.

Duodenal ulcer: 30 mg daily in the morning for 4 weeks; maintenance 15 mg.

NSAID-associated duodenal or gastric ulcer: 15-30 mg daily for 4 weeks, followed by a further 4 weeks if not fully healed.

Zollinger-Ellison syndrome (and other hypersecretory conditions): Initially 60 mg once daily adjusted according to response; daily doses of 120 mg or more is given in two divided doses.

Gastroesophageal reflux disease: 30 mg daily in the morning for 4 weeks, followed by a further 4 weeks if not fully healed; maintenance 15-30 mg daily.

Acid-related dyspepsia: 15-30 mg daily in the morning for 2-4 weeks

Lansoprazole is contraindicated in patients with known hypersensitivity to any component of the formulation.

Severe or irreversible adverse effects: The possible induction of carcinoid tumors by profound acid suppression and a rise in serum gastrin may occur. There is a rise in serum gastrin levels in the first 3 months of treatment, which are then maintained though at a lower level than those found in pernicious anemia. Long-term treatment with a proton pump inhibitor in patients with Helicobacter pylori infection may accelerate the development of atrophic gastritis.

Symptomatic adverse effect: Dose-dependent diarrhea occurs with an incidence of about 4% at 30 mg per day, rising to 8% at 60 mg per day. Headache occurs in 2-3% of treated patients.

Lansoprazole should be avoided in pregnancy unless there are compelling reasons.

Gastric malignancy should be ruled out. Hepatic impairment. Pregnancy and lactation.

Neonates: There is no relevant human data. The drug is not recommended for use with neonates.

Children: The youngest person to have received Lansoprazole in clinical trials was 13 years old.

The Elderly: No problems have been encountered in clinical use, and there has been no increase in adverse drug reactions in the elderly.

Proton Pump Inhibitor

Store at 25°C.